{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abrocitinib+200+mg",
    "query": {
      "intervention": "Abrocitinib 200 mg"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 21,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abrocitinib+200+mg&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T22:31:03.147Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04564755",
      "title": "Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "abrocitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2024-10-29",
      "last_synced_at": "2026-09-26T22:31:03.147Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Lancaster, California • Long Beach, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04564755"
    },
    {
      "nct_id": "NCT02201524",
      "title": "Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "PF-04965842",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 59,
      "start_date": "2014-11",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2016-10-05",
      "last_synced_at": "2026-09-26T22:31:03.147Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Rogers, Arkansas • Encinitas, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02201524"
    },
    {
      "nct_id": "NCT03915496",
      "title": "Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "PF-04965842 200 mg",
          "type": "DRUG"
        },
        {
          "name": "PF-04965842 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2020-06-18",
      "completion_date": "2021-11-16",
      "has_results": true,
      "last_update_posted_date": "2023-02-08",
      "last_synced_at": "2026-09-26T22:31:03.147Z",
      "location_count": 9,
      "location_summary": "Encinitas, California • Los Angeles, California • Largo, Florida + 5 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Largo",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03915496"
    },
    {
      "nct_id": "NCT04903093",
      "title": "A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Abrocitinib tablet",
          "type": "DRUG"
        },
        {
          "name": "Abrocitinib Suspension F1",
          "type": "DRUG"
        },
        {
          "name": "Abrocitinib Suspension F2",
          "type": "DRUG"
        },
        {
          "name": "Abrocitinib Suspension F3",
          "type": "DRUG"
        },
        {
          "name": "Abrocitinib Suspension F4",
          "type": "DRUG"
        },
        {
          "name": "Abrocitinib Suspension F5",
          "type": "DRUG"
        },
        {
          "name": "Abrocitinib Suspension F6",
          "type": "DRUG"
        },
        {
          "name": "Famotidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 19,
      "start_date": "2021-06-04",
      "completion_date": "2021-10-26",
      "has_results": true,
      "last_update_posted_date": "2024-11-14",
      "last_synced_at": "2026-09-26T22:31:03.147Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04903093"
    },
    {
      "nct_id": "NCT04345367",
      "title": "Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Abrocitinib 200 mg",
          "type": "DRUG"
        },
        {
          "name": "Dupilumab 300 mg",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 727,
      "start_date": "2020-06-11",
      "completion_date": "2021-07-13",
      "has_results": true,
      "last_update_posted_date": "2022-07-08",
      "last_synced_at": "2026-09-26T22:31:03.147Z",
      "location_count": 49,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 39 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04345367"
    },
    {
      "nct_id": "NCT03796676",
      "title": "JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "PF-04965842",
          "type": "DRUG"
        },
        {
          "name": "PF04965842",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 287,
      "start_date": "2019-02-18",
      "completion_date": "2020-04-08",
      "has_results": true,
      "last_update_posted_date": "2022-04-13",
      "last_synced_at": "2026-09-26T22:31:03.147Z",
      "location_count": 52,
      "location_summary": "Birmingham, Alabama • Madera, California • Mission Viejo, California + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Madera",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Doral",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03796676"
    },
    {
      "nct_id": "NCT03720470",
      "title": "Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dermatitis",
        "Dermatitis, Atopic",
        "Eczema",
        "Skin Diseases",
        "Skin Diseases, Genetic",
        "Genetic Diseases, Inborn",
        "Skin Diseases, Eczematous",
        "Hypersensitivity",
        "Hypersensitivity, Immediate",
        "Immune System Diseases"
      ],
      "interventions": [
        {
          "name": "PF-04965842 100 mg",
          "type": "DRUG"
        },
        {
          "name": "PF-04965842 200 mg",
          "type": "DRUG"
        },
        {
          "name": "Dupilumab",
          "type": "DRUG"
        },
        {
          "name": "Oral Placebo",
          "type": "DRUG"
        },
        {
          "name": "Injectable Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 838,
      "start_date": "2018-10-29",
      "completion_date": "2020-03-06",
      "has_results": true,
      "last_update_posted_date": "2021-01-19",
      "last_synced_at": "2026-09-26T22:31:03.147Z",
      "location_count": 60,
      "location_summary": "Birmingham, Alabama • Huntington Beach, California • Laguna Hills, California + 52 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03720470"
    },
    {
      "nct_id": "NCT05743244",
      "title": "Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Abrocitinib 200 MG Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Ritlecitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "12 Years to 35 Years"
      },
      "enrollment_count": 78,
      "start_date": "2023-10-19",
      "completion_date": "2027-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-09-26T22:31:03.147Z",
      "location_count": 23,
      "location_summary": "Orange, California • Palo Alto, California • San Francisco, California + 20 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05743244"
    },
    {
      "nct_id": "NCT05650736",
      "title": "Janus Kinase Inhibition in Granuloma Annulare",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Granuloma Annulare"
      ],
      "interventions": [
        {
          "name": "Abrocitinib 200 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "William Damsky",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2023-10-27",
      "completion_date": "2025-07-01",
      "has_results": false,
      "last_update_posted_date": "2025-03-04",
      "last_synced_at": "2026-09-26T22:31:03.147Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05650736"
    },
    {
      "nct_id": "NCT02780167",
      "title": "Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "PF-04965842",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 269,
      "start_date": "2016-04",
      "completion_date": "2017-04",
      "has_results": true,
      "last_update_posted_date": "2019-05-02",
      "last_synced_at": "2026-09-26T22:31:03.147Z",
      "location_count": 37,
      "location_summary": "Birmingham, Alabama • Encinitas, California • Pasadena, California + 32 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02780167"
    }
  ]
}